3. Melamede, R. Harm reduction--the cannabis paradox. Harm Reduct J 2, 17 (2005).
4. Burstein, S. H. & Zurier, R. B. Cannabinoids, Endocannabinoids, and Related Analogs in Inflammation. AAPS J (2009).
5. Melamede, R. J. Endocannabinoids: Multi-scaled, Global Homeostatic Regulators of Cells and Society. Interjournal Complex Systems 1669 (2006).
6. Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M. & Bonner, T. I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U S A 96, 5780-5785 (1999).
7. Mach, F. & Steffens, S. The role of the endocannabinoid system in atherosclerosis. J. Neuroendocrinol. 20 Suppl 1, 53-57 (2008).
8. Pacher, P. & Hasko, G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br. J. Pharmacol. (2008).
9. Hosking, R. D. & Zajicek, J. P. Therapeutic potential of cannabis in pain medicine. Br J Anaesth (2008).
10. Rog, D. J., Nurmikko, T. J. & Young, C. A. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 29, 2068-2079 (2007).
11. Cabral, G. A., Raborn, E. S., Griffin, L., Dennis, J. & Marciano-Cabral, F. CB(2) receptors in the brain: role in central immune function. Br. J. Pharmacol. (2007).
12. Eisenstein, T. K., Meissler, J. J., Wilson, Q., Gaughan, J. P. & Adler, M. W. Anandamide and Delta(9)Âtetrahydrocannabinol directly inhibit cells of the immune system via CB(2) receptors. J. Neuroimmunol. (2007).
13. Klein, T. W. & Cabral, G. A. Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol 1, 50-64 (2006).
